LYT-200
The FDA has granted an orphan drug designation to LYT-200, a fully human IgG4 monoclonal antibody targeting galectin-9, for use as a potential therapeutic option for patients with pancreatic cancer.1
Galectin-9 serves as a key regulator of the immune response to cancer and may work in concert with PD-1 which alone can be targeted to improve the immune systems response to cancer. Galectin-9 is highly expressed across pancreatic cancer and cholangiocarcinoma, two types of cancer that respond poorly to chemotherapy and immunotherapy. A multicenter phase 1/2 study (NCT04666688) is evaluating the safety, and antitumor activity of LYT-200 both as a single agent, and in combination with either chemotherapy or anti–PD-1 therapy in patients with cholangiocarcinoma and pancreatic cancer.
FDA authorizes SNK01 natural killer cell therapy for compassionate use in sarcomas.
FDA authorizes SNK01 natural killer cell therapy for compassionate use in sarcomas.
Lynparza Delays Progression & Significantly Prolongs Survival in Ovarian Cancer
5 Year follow up data - Lynparza maintenance therapy effective for women with BRCA + and other mutated ovarian cancers.
References
1. PureTech receives orphan drug designation for wholly owned candidate LYT-200 for the treatment of pancreatic cancer. News release. PureTech Health PLC. November 11, 2021. Accessed November 11, 2021. https://bit.ly/3D7vkEz
2. Monoclonal antibody targeting galectin-9 in development for the potential treatment of solid tumors. PureTech Health PLC website. Accessed November 11, 2021. https://bit.ly/3He60yX
3. LYT-200 alone and in combination with chemotherapy or anti-PD-1 in patients with metastatic solid tumors. ClinicalTrials.gov. Updated April 6, 2021. Accessed November 11, 2021. https://clinicaltrials.gov/ct2/show/NCT04666688
